Disease Detail

ID DOID:1909
Name melanoma
Definition A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer melanoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Dabrafenib melanoma sensitive detail...
BRAF V600E Vemurafenib melanoma sensitive detail...
NRAS mutant Binimetinib melanoma conflicting detail...
BRAF wild-type Dabrafenib melanoma no benefit detail...
BRAF V600E/K Trametinib melanoma sensitive detail...
MAP2K1 Q56P BRAF V600E Selumetinib melanoma resistant detail...
BRAF V600E RXDX-105 melanoma sensitive detail...
Unknown unknown Lenvatinib melanoma not applicable detail...
BRAF wild-type RAF265 melanoma predicted - sensitive detail...
BRAF V600E PLX4720 melanoma sensitive detail...
BRAF wild-type PLX4720 melanoma resistant detail...
MAP2K1 Q56P BRAF V600E PLX4720 melanoma resistant detail...
MAP2K1 Q56P BRAF V600E PLX4720 + Selumetinib melanoma sensitive detail...
Unknown unknown Alisertib melanoma not applicable detail...
BRAF V600E Sorafenib melanoma no benefit detail...
BRAF act mut Sorafenib melanoma no benefit detail...
Unknown unknown Ramucirumab melanoma not applicable detail...
Unknown unknown Axitinib melanoma not applicable detail...
Unknown unknown Gemcitabine + Pazopanib melanoma not applicable detail...
BRAF act mut Cobimetinib melanoma sensitive detail...
Unknown unknown Dovitinib melanoma not applicable detail...
MAP2K1 K57E Dabrafenib melanoma resistant detail...
Unknown unknown Vandetanib melanoma not applicable detail...
BRAF V600E Encorafenib melanoma sensitive detail...
NRAS mutant Adavosertib melanoma sensitive detail...
BRAF L597S TAK-733 melanoma sensitive detail...
BRAF mutant Selumetinib melanoma sensitive detail...
BRAF wild-type Selumetinib melanoma no benefit detail...
KIT N505I Sorafenib melanoma sensitive detail...
KIT N505I Imatinib melanoma predicted - sensitive detail...
BRAF V600X Binimetinib melanoma sensitive detail...
BRAF V600E Binimetinib melanoma sensitive detail...
BRAF mutant MLN2480 melanoma sensitive detail...
Unknown unknown PD-0325901 melanoma not applicable detail...
BRAF V600E Refametinib melanoma sensitive detail...
BRAF V600E Selumetinib melanoma sensitive detail...
Unknown unknown Cobimetinib melanoma not applicable detail...
BRAF V600X Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E PTEN loss Everolimus melanoma predicted - resistant detail...
BRAF wild-type Trametinib melanoma sensitive detail...
BRAF V600E Ganetespib + TAK-733 melanoma sensitive detail...
KDR positive Anti-VEGFR2 CAR CD8 lymphocytes melanoma predicted - sensitive detail...
Unknown unknown Dizocilpine melanoma not applicable detail...
BRAF L505H Vemurafenib melanoma resistant detail...
BRAF V600K Dabrafenib melanoma sensitive detail...
BRAF V600X Dabrafenib melanoma sensitive detail...
BRAF V600X Vemurafenib melanoma sensitive detail...
BRAF V600E/K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600X Dabrafenib + Trametinib melanoma sensitive detail...
BRAF mut + TP53 wild-type CGM097 + Encorafenib melanoma sensitive detail...
KIT A829P Imatinib melanoma resistant detail...
KIT A829P Sunitinib melanoma resistant detail...
KIT A829P Nilotinib melanoma sensitive detail...
KIT A829P Dasatinib melanoma sensitive detail...
KIT T670I Imatinib melanoma resistant detail...
KIT T670I Nilotinib melanoma resistant detail...
KIT T670I Dasatinib melanoma resistant detail...
KIT T670I Sunitinib melanoma sensitive detail...
MAP2K1 P124L Selumetinib melanoma resistant detail...
KIT act mut Imatinib melanoma sensitive detail...
Unknown unknown Nab-paclitaxel + Oblimersen + Temozolomide melanoma not applicable detail...
Unknown unknown Fresolimumab melanoma not applicable detail...
NRAS mutant Binimetinib + Ribociclib melanoma sensitive detail...
CDKN2A loss NRAS mutant Abemaciclib melanoma sensitive detail...
CDKN2A loss Alvocidib melanoma sensitive detail...
BRAF V600E NRAS Q61K XL888 melanoma sensitive detail...
BRAF V600E NRAS Q61K Vemurafenib melanoma resistant detail...
Unknown unknown Ipilimumab melanoma not applicable detail...
BRAF mutant PLX8394 melanoma sensitive detail...
BRAF V600E Navitoclax + PLX4720 melanoma sensitive detail...
NRAS Q61K CDKN2A loss Palbociclib + Trametinib melanoma sensitive detail...
Unknown unknown NMS-P715 melanoma not applicable detail...
KIT mutant Nilotinib melanoma sensitive detail...
BRAF V600E CCT196969 melanoma sensitive detail...
BRAF V600E CCT241161 melanoma sensitive detail...
BRAF V600D CCT196969 melanoma sensitive detail...
BRAF V600D CCT241161 melanoma sensitive detail...
NRAS Q61L CCT241161 melanoma sensitive detail...
NRAS Q61L CCT196969 melanoma sensitive detail...
NRAS Q61L PLX4720 melanoma resistant detail...
NRAS mutant CCT196969 melanoma sensitive detail...
NRAS mutant CCT241161 melanoma sensitive detail...
BRAF V600E Gefitinib + PLX4720 melanoma sensitive detail...
BRAF V600E Dasatinib melanoma sensitive detail...
BRAF V600E Saracatinib melanoma sensitive detail...
BRAF V600E S3I-201 melanoma sensitive detail...
BRAF V600E BRAF L505H Vemurafenib melanoma predicted - resistant detail...
BRAF mut NRAS mut Lenvatinib melanoma sensitive detail...
BRAF V600E BI-69A11 melanoma sensitive detail...
BRAF V600E SBI-0640756 melanoma sensitive detail...
BRAF V600E SBI-0640726 melanoma sensitive detail...
NRAS mutant BI-69A11 melanoma sensitive detail...
NRAS mutant SBI-0640756 melanoma sensitive detail...
NRAS mutant SBI-0640726 melanoma sensitive detail...
BRAF V600E SBI-755199 melanoma sensitive detail...
BRAF V600E SBI-0640756 + Vemurafenib melanoma sensitive detail...
NRAS Q61K CDKN2A loss SBI-0640756 melanoma sensitive detail...
BRAF mut NRAS wild-type Lenvatinib melanoma sensitive detail...
BRAF wild-type NRAS mutant Lenvatinib melanoma sensitive detail...
BRAF wild-type NRAS wild-type Lenvatinib melanoma sensitive detail...
EZH2 Y646N GSK126 melanoma sensitive detail...
BRAF V600E E6201 melanoma sensitive detail...
BRAF V600E MAP2K1 C121S E6201 melanoma sensitive detail...
BRAF V600E MAP2K1 C121S Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 C121S Selumetinib melanoma decreased response detail...
PTEN wild-type E6201 melanoma sensitive detail...
TP53 wild-type RB1 wild-type R547 melanoma sensitive detail...
PTEN dec exp Pembrolizumab melanoma decreased response detail...
PTEN dec exp Nivolumab melanoma decreased response detail...
PTEN positive Pembrolizumab melanoma sensitive detail...
PTEN positive Nivolumab melanoma sensitive detail...
PTEN loss GSK2636771 melanoma sensitive detail...
BRAF mut PTEN loss GSK2636771 + Pembrolizumab melanoma sensitive detail...
BRAF mut PTEN loss GSK2636771 melanoma no benefit detail...
BRAF mut PTEN loss Pembrolizumab melanoma no benefit detail...
BRAF V600E Navitoclax + Vemurafenib melanoma sensitive detail...
BRAF V600E Navitoclax + Trametinib melanoma sensitive detail...
BRAF V600E Trametinib + TW-37 melanoma sensitive detail...
BRAF V600E TW-37 + Vemurafenib melanoma sensitive detail...
NRAS mutant Tubastatin A melanoma sensitive detail...
BRAF mutant Tubastatin A melanoma sensitive detail...
Unknown unknown AT13148 melanoma not applicable detail...
Unknown unknown CCT129254 melanoma not applicable detail...
BRAF V600E Cediranib + PLX4720 melanoma sensitive detail...
BRAF V600E PLX4720 + Selumetinib melanoma sensitive detail...
BRAF V600E Cediranib + PLX4720 + Selumetinib melanoma sensitive detail...
BRAF V600E PLX4720 + Tivozanib melanoma sensitive detail...
PTEN dec exp SAR260301 melanoma sensitive detail...
BRAF V600E BI 882370 + Trametinib melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type Selumetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type BEZ235 + Vemurafenib melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type Vemurafenib + ZSTK474 melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type Selumetinib + ZSTK474 melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type BEZ235 + Selumetinib melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type A66 melanoma no benefit detail...
BRAF V600E/K PIK3CA wild-type TGX-221 melanoma no benefit detail...
BRAF V600E/K PIK3CA wild-type Idelalisib melanoma no benefit detail...
Unknown unknown Sirtinol melanoma not applicable detail...
Unknown unknown Ex-527 melanoma not applicable detail...
ALK wild-type Dalantercept + Doxorubicin melanoma sensitive detail...
KDR Q472H unspecified VEGFR2 antibody melanoma sensitive detail...
BRAF V600E DEL-22379 melanoma sensitive detail...
EZH2 Y641H GSK126 melanoma predicted - sensitive detail...
EZH2 Y641N GSK126 melanoma predicted - sensitive detail...
EZH2 wild-type GSK126 melanoma predicted - sensitive detail...
EZH2 Y641S GSK126 melanoma predicted - sensitive detail...
BRAF mutant E6201 melanoma sensitive detail...
NRAS wild-type E6201 melanoma sensitive detail...
HRAS wild-type E6201 melanoma sensitive detail...
BRAF mutant E6201 + LY294002 melanoma sensitive detail...
BRAF mut PTEN mut E6201 melanoma decreased response detail...
BRAF mut PTEN wild-type E6201 melanoma sensitive detail...
BRAF V600E SCH772984 melanoma sensitive detail...
BRAF V600E PD-0325901 melanoma conflicting detail...
HRAS G12V CI-1040 melanoma sensitive detail...
BRAF V600E NRAS G12V Vemurafenib melanoma resistant detail...
BRAF V600E NRAS G12V DEL-22379 melanoma sensitive detail...
BRAF V600E MAP2K1 I103N PD-0325901 melanoma resistant detail...
BRAF V600E MAP2K1 L115P PD-0325901 melanoma resistant detail...
BRAF V600E MAP2K1 I103N DEL-22379 melanoma sensitive detail...
BRAF V600E MAP2K1 L115P DEL-22379 melanoma sensitive detail...
BRAF V600E MAP2K1 V211D CI-1040 melanoma resistant detail...
BRAF V600E MAP2K1 V211D Selumetinib melanoma resistant detail...
BRAF mutant Vemurafenib + Voruciclib melanoma sensitive detail...
BRAF V600E NRAS Q61K Dabrafenib melanoma resistant detail...
BRAF V600E NRAS A146T MAP2K1 P387S Dabrafenib melanoma resistant detail...
BRAF V600E NRAS A146T Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P387S NRAS Q61K Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 K59del Dabrafenib melanoma resistant detail...
BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S Dabrafenib melanoma resistant detail...
BRAF V600E NRAS A146T Vemurafenib melanoma resistant detail...
BRAF V600E NRAS A146T MAP2K1 P387S Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 K59del Vemurafenib melanoma resistant detail...
BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S Vemurafenib melanoma resistant detail...
BRAF V600E NRAS A146T Trametinib melanoma decreased response detail...
BRAF V600E NRAS A146T MAP2K1 P387S Trametinib melanoma decreased response detail...
BRAF V600E MAP2K1 P387S NRAS Q61K Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P387S NRAS Q61K Trametinib melanoma decreased response detail...
BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 K59del Trametinib melanoma resistant detail...
BRAF V600E NRAS A146T GSK2126458 melanoma decreased response detail...
BRAF V600E NRAS A146T MAP2K1 P387S GSK2126458 melanoma decreased response detail...
BRAF V600E MAP2K1 P387S NRAS Q61K GSK2126458 melanoma decreased response detail...
BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S GSK2126458 melanoma decreased response detail...
BRAF V600E MAP2K1 K59del GSK2126458 melanoma decreased response detail...
BRAF V600E GSK2126458 melanoma sensitive detail...
BRAF V600K NRAS Q61K Dabrafenib melanoma resistant detail...
BRAF V600K NRAS Q61K Trametinib melanoma decreased response detail...
BRAF V600K GSK2126458 melanoma sensitive detail...
BRAF V600K NRAS Q61K GSK2126458 melanoma sensitive detail...
BRAF V600E MAP2K1 Q56P Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q56P Trametinib melanoma decreased response detail...
BRAF V600E NRAS A146T Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E NRAS Q61K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E NRAS Q61K NRAS A146T Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 K59del Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600K NRAS Q61K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 Q56P Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 K59del Dabrafenib + GSK2126458 melanoma sensitive detail...
BRAF V600E MAP2K1 K59del GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E Dabrafenib + GSK2126458 melanoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E NRAS A146T Dabrafenib + GSK2126458 melanoma sensitive detail...
BRAF V600E NRAS A146T MAP2K1 P387S Dabrafenib + GSK2126458 melanoma no benefit detail...
BRAF V600E MAP2K1 P387S NRAS Q61K Dabrafenib + GSK2126458 melanoma conflicting detail...
BRAF V600E NRAS A146T GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E NRAS A146T MAP2K1 P387S GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S NRAS Q61K GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600K NRAS Q61K GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600K NRAS Q61K Dabrafenib + GSK2126458 melanoma sensitive detail...
BRAF V600E CSF1R positive Pexidartinib + Vemurafenib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 melanoma sensitive detail...
BRAF mut PTEN inact mut TGX-221 melanoma sensitive detail...
BRAF mut PTEN inact mut Pictilisib melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib melanoma decreased response detail...
BRAF mut PTEN inact mut Alpelisib + AZD6482 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + GSK2636771 melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut GSK2636771 + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut NVP-AEW541 + Pictilisib melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + NVP-AEW541 melanoma no benefit detail...
BRAF mut PTEN wild-type AZD6482 + NVP-AEW541 melanoma no benefit detail...
BRAF mut PTEN wild-type GSK2636771 + NVP-AEW541 melanoma no benefit detail...
BRAF mut PTEN inact mut Encorafenib + Pictilisib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Encorafenib melanoma sensitive detail...
BRAF mut PTEN inact mut Encorafenib + GSK2636771 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + Encorafenib melanoma no benefit detail...
BRAF mut PTEN inact mut Binimetinib + Pictilisib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Binimetinib melanoma sensitive detail...
BRAF mut PTEN inact mut Binimetinib + GSK2636771 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + Binimetinib melanoma no benefit detail...
BRAF mut PTEN wild-type AZD6482 + Binimetinib melanoma no benefit detail...
BRAF mut PTEN wild-type Binimetinib + GSK2636771 melanoma no benefit detail...
BRAF mut PTEN wild-type AZD6482 + Encorafenib melanoma no benefit detail...
BRAF mut PTEN wild-type Encorafenib + GSK2636771 melanoma no benefit detail...
BRAF mut PTEN inact mut Alpelisib + AZD6482 + Encorafenib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Encorafenib + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + AZD6482 + Binimetinib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Binimetinib + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Binimetinib + Encorafenib + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + AZD6482 + Binimetinib + Encorafenib melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + Encorafenib + GSK2636771 melanoma sensitive detail...
BRAF mut PTEN inact mut GSK2636771 + unspecified IGF-1R antibody melanoma sensitive detail...
BRAF mut PTEN inact mut Encorafenib + unspecified IGF-1R antibody melanoma sensitive detail...
BRAF mut PTEN inact mut Encorafenib + GSK2636771 + unspecified IGF-1R antibody melanoma sensitive detail...
MET over exp XL147 melanoma sensitive detail...
BRAF V600E PTEN loss XL147 melanoma sensitive detail...
BRAF V600D PTEN loss XL147 melanoma sensitive detail...
Unknown unknown Nivolumab melanoma not applicable detail...
Unknown unknown E7449 + Temozolomide melanoma not applicable detail...
BRAF V600E LY3009120 melanoma sensitive detail...
NRAS Q61K LY3009120 melanoma sensitive detail...
BRAF G469R NRAS Q61K LY3009120 melanoma sensitive detail...
NRAS G13D LY3009120 melanoma sensitive detail...
NRAS Q61L LY3009120 melanoma decreased response detail...
TP53 D259Y LY3009120 melanoma sensitive detail...
NRAS Q61K Selumetinib melanoma sensitive detail...
NRAS G13D Selumetinib melanoma sensitive detail...
BRAF G469R NRAS Q61K Selumetinib melanoma decreased response detail...
NRAS Q61L Selumetinib melanoma decreased response detail...
TP53 D259Y Selumetinib melanoma sensitive detail...
TP53 D259Y Vemurafenib melanoma sensitive detail...
NRAS Q61K Vemurafenib melanoma resistant detail...
NRAS G13D Vemurafenib melanoma resistant detail...
NRAS Q61L Vemurafenib melanoma resistant detail...
BRAF G469R NRAS Q61K Vemurafenib melanoma resistant detail...
NRAS mutant Vemurafenib melanoma resistant detail...
NRAS mutant LY3009120 melanoma sensitive detail...
BRAF V600E DETD-35 melanoma sensitive detail...
BRAF V600E DETD-35 + Vemurafenib melanoma sensitive detail...
PTEN loss DETD-35 melanoma sensitive detail...
PTEN loss DETD-35 + Vemurafenib melanoma sensitive detail...
MAP2K1 V60E Trametinib melanoma resistant detail...
MAP2K1 V60E Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 H119P Selumetinib melanoma resistant detail...
BRAF V600E MAP2K1 V60E VRT11E melanoma sensitive detail...
BRAF V600E MAP2K1 C121S VRT11E melanoma sensitive detail...
BRAF V600E MAP2K1 P124S VRT11E melanoma sensitive detail...
BRAF V600E MAP2K1 G128V VRT11E melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 C121S Dabrafenib + Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 G128V Dabrafenib + Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 P124S Selumetinib melanoma decreased response detail...
BRAF V600E MAP2K1 C121S PLX4720 melanoma resistant detail...
BRAF V600E MAP2K1 V60E Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P124S Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 G128V Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 G128V Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 P124S Trametinib melanoma resistant detail...
BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R Vemurafenib melanoma predicted - resistant detail...
BRAF amp BRAF V600X NRAS Q61K Vemurafenib melanoma resistant detail...
BRAF V600E PTEN loss Pictilisib + PLX4720 melanoma sensitive detail...
BRAF V600X PIK3CA H1047R PTEN Y86fs Vemurafenib melanoma resistant detail...
BRAF V600X PTEN H93D Vemurafenib melanoma predicted - sensitive detail...
Unknown unknown Pembrolizumab melanoma not applicable detail...
BRAF V600E BGB-283 melanoma sensitive detail...
ERBB4 E317K Lapatinib melanoma sensitive detail...
ERBB4 E452K Lapatinib melanoma sensitive detail...
ERBB4 R544W Lapatinib melanoma sensitive detail...
ERBB4 E563K Lapatinib melanoma sensitive detail...
ERBB4 R393W Lapatinib melanoma sensitive detail...
Unknown unknown Abemaciclib melanoma not applicable detail...
JAK2 inact mut Pembrolizumab melanoma predicted - resistant detail...
BRAF V600E SHP099 melanoma no benefit detail...
BRAF V600E MAP2K1 K57E Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P124Q Dabrafenib melanoma decreased response detail...
BRAF V600K MAP2K1 P124Q Dabrafenib melanoma decreased response detail...
BRAF V600K MAP2K1 P124L Dabrafenib melanoma decreased response detail...
BRAF V600K MAP2K1 P124L VX-11e melanoma sensitive detail...
BRAF V600K MAP2K1 P124Q VX-11e melanoma sensitive detail...
BRAF V600K MAP2K1 P124Q Trametinib melanoma sensitive detail...
BRAF V600K MAP2K1 P124L Trametinib melanoma sensitive detail...
Unknown unknown Ipilimumab + Radiotherapy melanoma not applicable detail...
KIT L576P Bevacizumab + Sorafenib melanoma predicted - sensitive detail...
BRAF mut PTEN loss SAR260301 melanoma sensitive detail...
BRAF mut PTEN loss SAR260301 + Vemurafenib melanoma sensitive detail...
BRAF mut PTEN loss SAR260301 + Selumetinib melanoma sensitive detail...
Unknown unknown Cediranib melanoma no benefit detail...
BRAF mut STAG2 dec exp Dabrafenib melanoma decreased response detail...
BRAF mut STAG2 dec exp Vemurafenib melanoma decreased response detail...
BRAF mut STAG2 dec exp Trametinib melanoma decreased response detail...
BRAF mut STAG2 dec exp Dabrafenib + Trametinib melanoma decreased response detail...
NRAS mut STAG2 dec exp Trametinib melanoma decreased response detail...
BRAF V600E BI-847325 melanoma sensitive detail...
BRAF mutant BI-847325 melanoma predicted - sensitive detail...
BRAF mut NRAS mut BI-847325 melanoma predicted - sensitive detail...
BRAF V600E PAC-1 + Vemurafenib melanoma sensitive detail...
BRAF V600E PAC-1 + Trametinib + Vemurafenib melanoma sensitive detail...
BRAF V600E GDC0879 melanoma sensitive detail...
BRAF wild-type NRAS Q61K GDC0879 melanoma resistant detail...
BRAF wild-type GDC0879 melanoma resistant detail...
BRAF V600E PTEN loss GDC0879 + Pictilisib melanoma sensitive detail...
BRAF V600E PLX7904 melanoma sensitive detail...
BRAF V600E AZ628 melanoma sensitive detail...
BRAF V600D AZ628 melanoma sensitive detail...
BRAF G466E AZ628 melanoma sensitive detail...
BRAF V600R AZ628 melanoma sensitive detail...
BRAF D594G NRAS G12D AZ628 melanoma sensitive detail...
BRAF wild-type NRAS wild-type AZ628 melanoma sensitive detail...
BRAF V600E TAK-632 melanoma sensitive detail...
BRAF V600D TAK-632 melanoma sensitive detail...
BRAF G466E TAK-632 melanoma sensitive detail...
BRAF V600R TAK-632 melanoma sensitive detail...
BRAF D594G NRAS G12D TAK-632 melanoma sensitive detail...
BRAF wild-type NRAS wild-type TAK-632 melanoma sensitive detail...
BRAF V600E SB590885 melanoma sensitive detail...
BRAF V600D PLX7904 melanoma sensitive detail...
BRAF G466E PLX7904 melanoma decreased response detail...
BRAF V600R PLX7904 melanoma sensitive detail...
BRAF D594G NRAS G12D PLX7904 melanoma decreased response detail...
BRAF wild-type NRAS wild-type PLX7904 melanoma resistant detail...
BRAF V600D Vemurafenib melanoma sensitive detail...
BRAF V600R Vemurafenib melanoma sensitive detail...
BRAF G466E Vemurafenib melanoma decreased response detail...
BRAF D594G NRAS G12D Vemurafenib melanoma decreased response detail...
BRAF wild-type NRAS wild-type Vemurafenib melanoma resistant detail...
BRAF V600D Dabrafenib melanoma sensitive detail...
BRAF V600R Dabrafenib melanoma sensitive detail...
BRAF G466E Dabrafenib melanoma decreased response detail...
BRAF D594G NRAS G12D Dabrafenib melanoma decreased response detail...
BRAF mut + TP53 wild-type AMG 232 melanoma sensitive detail...
AKT1 E17K BRAF V600X PTEN pos Vemurafenib melanoma resistant detail...
AKT1 Q79K BRAF V600X PTEN pos Vemurafenib melanoma resistant detail...
AKT1 Q79K BRAF V600X PTEN pos MK2206 + Vemurafenib melanoma sensitive detail...
BRAF V600X Trametinib + Vemurafenib melanoma sensitive detail...
BRAF V600X Selumetinib + Vemurafenib melanoma sensitive detail...
BRAF V600X Buparlisib + Vemurafenib melanoma sensitive detail...
BRAF V600X Buparlisib + Trametinib melanoma sensitive detail...
BRAF V600X Buparlisib + Selumetinib melanoma sensitive detail...
BRAF V600X MK2206 + Vemurafenib melanoma sensitive detail...
BRAF V600X MK2206 + Trametinib melanoma sensitive detail...
BRAF V600X PTEN neg Uprosertib melanoma sensitive detail...
TP53 wild-type AMG 232 melanoma sensitive detail...
TP53 wild-type AMG 232 + Radiotherapy melanoma sensitive detail...
Unknown unknown AS1409 melanoma not applicable detail...
BRAF V600E RO4987655 melanoma sensitive detail...
BRAF V600E RO5126766 melanoma sensitive detail...
BRAF wild-type Palbociclib melanoma sensitive detail...
NRAS wild-type Palbociclib melanoma sensitive detail...
BRAF mut RB1 loss Palbociclib melanoma decreased response detail...
CDKN2A loss Palbociclib melanoma resistant detail...
NRAS wild-type Trametinib melanoma sensitive detail...
BRAF mut RB1 loss Trametinib melanoma decreased response detail...
CDKN2A loss Trametinib melanoma sensitive detail...
BRAF mutant Palbociclib + Trametinib melanoma sensitive detail...
BRAF wild-type Palbociclib + Trametinib melanoma decreased response detail...
NRAS wild-type Palbociclib + Trametinib melanoma decreased response detail...
BRAF mut RB1 loss Palbociclib + Trametinib melanoma decreased response detail...
BRAF V600E Palbociclib melanoma no benefit detail...
BRAF V600E Palbociclib + PD-0325901 melanoma sensitive detail...
NRAS mutant PD-0325901 melanoma no benefit detail...
NRAS mutant Palbociclib melanoma conflicting detail...
NRAS mutant Palbociclib + PD-0325901 melanoma sensitive detail...
KIT L576P Dasatinib melanoma sensitive detail...
KIT exon 11 Imatinib melanoma predicted - sensitive detail...
KIT L576P Imatinib melanoma unknown detail...
KIT D820Y Sorafenib melanoma predicted - sensitive detail...
BRAF mutant S63845 + Trametinib melanoma sensitive detail...
NRAS mutant S63845 + Trametinib melanoma sensitive detail...
BRAF mutant S63845 + Vemurafenib melanoma sensitive detail...
Unknown unknown IMC-20D7S melanoma not applicable detail...
Unknown unknown LDC1267 melanoma not applicable detail...
BRAF V600E Imatinib + PLX4720 melanoma sensitive detail...
BRAF V600E Alpelisib + PLX4720 melanoma sensitive detail...
BRAF V600E PLX4720 + Vorinostat melanoma sensitive detail...
BRAF V600E Doxorubicin + PLX4720 melanoma sensitive detail...
BRAF V600E Erlotinib + PLX4720 melanoma sensitive detail...
Unknown unknown CCG-203971 melanoma not applicable detail...
Unknown unknown Denileukin diftitox + Sirolimus melanoma not applicable detail...
BRAF mutant Binimetinib + Buparlisib melanoma sensitive detail...
NRAS mutant Binimetinib + Buparlisib melanoma sensitive detail...
BRAF wild-type NRAS wild-type Binimetinib + Buparlisib melanoma sensitive detail...
BRAF mutant Buparlisib + Encorafenib melanoma sensitive detail...
BRAF mutant Buparlisib melanoma sensitive detail...
NRAS mutant Buparlisib melanoma sensitive detail...
Unknown unknown A-674563 melanoma not applicable detail...
BRAF V600E PIK3CA H1047K ARQ092 + Trametinib melanoma sensitive detail...
PTEN mutant BI-69A11 melanoma sensitive detail...
Unknown unknown Cabozantinib melanoma not applicable detail...
MAP2K1 L115P CI-1040 melanoma resistant detail...
MAP2K1 L115P Selumetinib melanoma resistant detail...
MAP2K1 I103N Selumetinib melanoma resistant detail...
MAP2K1 I103N CI-1040 melanoma resistant detail...
Unknown unknown GNE-317 melanoma not applicable detail...
TP53 wild-type APR-246 melanoma sensitive detail...
AKT1 E17K Uprosertib melanoma sensitive detail...
Unknown unknown Alvocidib melanoma no benefit detail...
BRAF V600E PTEN loss GSK2636771 + unspecified PD-1 antibody melanoma sensitive detail...
NRAS mutant Trametinib melanoma sensitive detail...
NRAS Q61L Binimetinib melanoma sensitive detail...
NRAS Q61K Binimetinib melanoma sensitive detail...
NRAS Q61R Binimetinib melanoma sensitive detail...
Unknown unknown GDC-0425 + Gemcitabine melanoma not applicable detail...
Unknown unknown V158411 melanoma not applicable detail...
BRAF V600E ASN003 melanoma sensitive detail...
BRAF V600E PTEN mut ASN003 melanoma sensitive detail...
BRAF V600X ASN003 melanoma sensitive detail...
KIT D816V NRAS Q61R Pembrolizumab + Trametinib melanoma no benefit detail...
CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H Carboplatin + Imatinib + Paclitaxel melanoma predicted - sensitive detail...
ATM mut NRAS Q61R Binimetinib melanoma predicted - sensitive detail...
Unknown unknown Ad5CMV-p53 gene + unspecified PD-1 antibody melanoma not applicable detail...
BRAF V600X AMG 232 + Dabrafenib + Trametinib melanoma sensitive detail...
Unknown unknown AMG 232 + Trametinib melanoma sensitive detail...
BRAF V600X Atezolizumab + Cobimetinib + Vemurafenib melanoma sensitive detail...
Unknown unknown JS001 melanoma not applicable detail...
BRAF mutant PET-16 + Vemurafenib melanoma sensitive detail...
KIT exon 11 Nilotinib melanoma sensitive detail...
KIT exon 13 Nilotinib melanoma sensitive detail...
KIT L576P Nilotinib melanoma sensitive detail...
KIT L576P KIT W557R Nilotinib melanoma sensitive detail...
KIT K642E Nilotinib melanoma sensitive detail...
KIT V559D Nilotinib melanoma sensitive detail...
KIT V559A Nilotinib melanoma sensitive detail...
KIT V560D Nilotinib melanoma sensitive detail...
KIT W557R Nilotinib melanoma sensitive detail...
BRAF V600E Encorafenib + Ribociclib melanoma sensitive detail...
Unknown unknown Epacadostat melanoma not applicable detail...
Unknown unknown G-TPP + Navitoclax melanoma not applicable detail...
Unknown unknown G-TPP + Obatoclax melanoma not applicable detail...
Unknown unknown G-TPP + WEHI-539 melanoma not applicable detail...
Unknown unknown G-TPP + Venetoclax melanoma not applicable detail...
Unknown unknown A-1210477 + G-TPP melanoma not applicable detail...
BRAF D594G Trametinib melanoma sensitive detail...
BRAF G466E HRAS Q61K Trametinib melanoma sensitive detail...
BRAF mutant KO-947 melanoma predicted - sensitive detail...
NRAS mutant KO-947 melanoma predicted - sensitive detail...
KIT V559A Imatinib melanoma predicted - sensitive detail...
Unknown unknown IMO-2125 melanoma not applicable detail...
BRAF V600E INU-152 melanoma sensitive detail...
BRAF K601E Trametinib melanoma predicted - sensitive detail...
BRAF K601E Dabrafenib melanoma no benefit detail...
BRAF V600E Cobimetinib melanoma sensitive detail...
BRAF mutant Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I111N Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 L115P Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 V211D Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 I111N Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L115P Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V211D Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V211D Ulixertinib melanoma sensitive detail...
BRAF V600E MAP2K1 C121S Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 E203K Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 E203K Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P124L Trametinib melanoma decreased response detail...
BRAF V600E MAP2K1 P124L Vemurafenib melanoma decreased response detail...
BRAF V600E MAP2K1 Q56P Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q56P Ulixertinib melanoma sensitive detail...
BRAF V600E MAP2K1 E203K Ulixertinib melanoma sensitive detail...
BRAF V600E EBI-907 melanoma sensitive detail...
BRAF V600E/K Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600K Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF mutant ST-162 melanoma predicted - sensitive detail...
BRAF mut PTEN mut ST-162 melanoma predicted - sensitive detail...
KIT D820Y Dasatinib melanoma sensitive detail...
KIT D820Y Imatinib melanoma resistant detail...
KIT D820Y SEL201 melanoma sensitive detail...
KIT L576P SEL201 melanoma sensitive detail...
BRAF V600E Dabrafenib + SCH772984 + Trametinib melanoma decreased response detail...
Unknown unknown CA-170 melanoma not applicable detail...
BRAF V600E RAF265 melanoma predicted - sensitive detail...
Unknown unknown DT01 + Radiotherapy melanoma not applicable detail...
BRAF mutant Ulixertinib melanoma predicted - sensitive detail...
NRAS mutant Ulixertinib melanoma predicted - sensitive detail...
BRAF V600K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E Trametinib melanoma sensitive detail...
BRAF V600K Trametinib melanoma sensitive detail...
BRAF V600K Vemurafenib melanoma sensitive detail...
ETV6-NTRK3 DS-6051a melanoma sensitive detail...
BRAF V600E RAF709 melanoma sensitive detail...
NRAS Q61K RAF709 melanoma predicted - sensitive detail...
NRAS Q61L RAF709 melanoma sensitive detail...
Unknown unknown Indoximod + Pembrolizumab melanoma not applicable detail...
Unknown unknown LN-144 melanoma not applicable detail...
BRAF V600E/K Binimetinib + Encorafenib melanoma sensitive detail...
Unknown unknown Nivolumab + NKTR-214 melanoma not applicable detail...
NRAS mutant Belvarafenib melanoma predicted - sensitive detail...
Unknown unknown Pembrolizumab + SD-101 melanoma not applicable detail...
Unknown unknown Ipilimumab + Nivolumab melanoma not applicable detail...
BRAF L514V BRAF V600E Vemurafenib melanoma decreased response detail...
BRAF L514V BRAF V600E Dabrafenib melanoma decreased response detail...
BRAF L514V BRAF V600E PLX8394 melanoma decreased response detail...
BRAF L514V BRAF V600E TAK-632 melanoma decreased response detail...
BRAF L514V BRAF V600E BGB3245 melanoma predicted - sensitive detail...
BRAF L514V BRAF V600E BGB3290 melanoma predicted - sensitive detail...
BRAF L514V BRAF V600E SCH772984 melanoma predicted - sensitive detail...
BRAF L514V BRAF V600E Trametinib melanoma decreased response detail...
BRAF L597S Encorafenib melanoma sensitive detail...
BRAF G469V Encorafenib melanoma no benefit detail...
BRAF G469V NRAS Q61K Encorafenib + Trametinib melanoma sensitive detail...
BRAF G469V NRAS Q61K Binimetinib + Encorafenib melanoma sensitive detail...
BRAF L597S Binimetinib + Encorafenib melanoma sensitive detail...
BRAF L597S Encorafenib + Trametinib melanoma sensitive detail...
BRAF G469V NRAS Q61K Trametinib + Vemurafenib melanoma predicted - resistant detail...
BRAF G469V NRAS Q61K LY3009120 melanoma sensitive detail...
BRAF L597S LY3009120 melanoma sensitive detail...
BRAF L597S Dabrafenib melanoma predicted - sensitive detail...
BRAF G469V NRAS Q61K Dabrafenib melanoma no benefit detail...
Unknown unknown Talimogene laherparepvec melanoma not applicable detail...
BRAF L597S BRAF R239Q Binimetinib + Encorafenib melanoma sensitive detail...
BRAF L597S BRAF R239Q Encorafenib melanoma sensitive detail...
BRAF L597S BRAF R239Q Binimetinib melanoma sensitive detail...
BRAF L597S Dabrafenib + Trametinib melanoma sensitive detail...
BRAF L597S BRAF R239Q Dabrafenib + Trametinib melanoma sensitive detail...
BRAF K601E BRAF S363F Encorafenib + Trametinib melanoma sensitive detail...
BRAF K601E BRAF S363F Encorafenib melanoma sensitive detail...
BRAF K601E BRAF S363F Dabrafenib + Trametinib melanoma sensitive detail...
BRAF K601E BRAF S363F Trametinib + Vemurafenib melanoma sensitive detail...
BRAF L597S Trametinib melanoma predicted - sensitive detail...
BRAF K601E BRAF S363F Trametinib melanoma sensitive detail...
BRAF L597S Cobimetinib melanoma sensitive detail...
BRAF K601E BRAF S363F Cobimetinib melanoma sensitive detail...
BRAF K601E BRAF S363F Binimetinib melanoma sensitive detail...
BRAF L597S Binimetinib melanoma sensitive detail...
BRAF V600E Ulixertinib melanoma sensitive detail...
BRAF V600K Pembrolizumab melanoma predicted - sensitive detail...
BRAF V600K Nivolumab melanoma predicted - sensitive detail...
BRAF V600E Nivolumab melanoma decreased response detail...
BRAF V600E Pembrolizumab melanoma decreased response detail...
BRAF V600E/K Vemurafenib + XL888 melanoma predicted - sensitive detail...
BRAF V600E RMC-4550 melanoma resistant detail...
NRAS over exp Binimetinib melanoma predicted - sensitive detail...
BRAF V600D NRAS dec exp Binimetinib melanoma no benefit detail...
NRAS amp Binimetinib melanoma predicted - sensitive detail...
BRAF wild-type Nivolumab melanoma predicted - sensitive detail...
BRAF V47_D380del Dabrafenib + Trametinib melanoma predicted - resistant detail...
Unknown unknown JSH-150 melanoma not applicable detail...
BRAF V600E Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600K Binimetinib + Encorafenib melanoma sensitive detail...
NRAS mutant Palbociclib + Trametinib melanoma predicted - sensitive detail...
AKT1 pos NRAS mut Palbociclib + Trametinib melanoma predicted - resistant detail...
NRAS mut PIK3CA E545K Palbociclib + Trametinib melanoma predicted - resistant detail...
EGFR L858R NRAS mut Palbociclib + Trametinib melanoma predicted - resistant detail...
AKT1 pos NRAS mut Trametinib melanoma predicted - resistant detail...
NRAS mut PIK3CA H1047R Trametinib melanoma predicted - resistant detail...
NRAS mut PIK3CA E545K Trametinib melanoma predicted - resistant detail...
Unknown unknown MIW815 + Spartalizumab melanoma not applicable detail...
BRAF mutant Belvarafenib melanoma predicted - sensitive detail...
Unknown unknown MBG453 + Spartalizumab melanoma not applicable detail...
AKT1 pos NRAS mut Palbociclib melanoma predicted - resistant detail...
EGFR L858R NRAS mut Trametinib melanoma decreased response detail...
KIT T632I Imatinib melanoma predicted - resistant detail...
NRAS mut PIK3CA E545K Palbociclib melanoma predicted - resistant detail...
EGFR L858R NRAS mut Palbociclib melanoma predicted - resistant detail...
NRAS mut NRAS Q61L Trametinib melanoma predicted - resistant detail...
NRAS mut NRAS Q61L Palbociclib + Trametinib melanoma predicted - resistant detail...
NRAS mut NRAS Q61L Palbociclib melanoma decreased response detail...
NRAS mut NRAS Q61K Trametinib melanoma predicted - resistant detail...
NRAS mut NRAS Q61K Palbociclib + Trametinib melanoma predicted - resistant detail...
NRAS mut NRAS Q61K Palbociclib melanoma decreased response detail...
NRAS mutant Pembrolizumab melanoma predicted - sensitive detail...
NRAS mutant Nivolumab melanoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00338377 Phase II Cyclophosphamide + Fludarabine Aldesleukin Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization Recruiting
NCT00492505 Phase II Cisplatin + Sorafenib + Tamoxifen Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma Unknown status
NCT00538005 Phase Ib/II Bevacizumab + Oxaliplatin + Sorafenib Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma Unknown status
NCT00700882 Phase II Dasatinib Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Active, not recruiting
NCT00925132 Phase Ib/II Decitabine + Panobinostat + Temozolomide Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat Terminated
NCT00976573 Everolimus Bevacizumab Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Completed
NCT01028222 Phase II Nilotinib A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation Completed
NCT01176474 Phase I NY-ESO-1 peptide vaccine Ipilimumab Nivolumab A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Active, not recruiting
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Completed
NCT01239134 Phase I TRX518 Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors Recruiting
NCT01258855 Phase II Aldesleukin Aflibercept Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Completed
NCT01274338 Phase III Ipilimumab Interferon alpha-2b Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Active, not recruiting
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT01303341 Phase I Riluzole + Sorafenib Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma Active, not recruiting
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed
NCT01321437 Phase II Axitinib Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Active, not recruiting
NCT01323517 Phase II Dactinomycin + Ipilimumab + Melphalan Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity Completed
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Active, not recruiting
NCT01409174 Phase Ib/II Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Terminated
NCT01425008 Phase I MLN2480 Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma Completed
NCT01436656 Phase I Encorafenib A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Active, not recruiting
NCT01449279 Phase I Ipilimumab Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy Active, not recruiting
NCT01480154 Phase I Hydroxychloroquine + MK2206 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting
NCT01495988 Phase II Bevacizumab Vemurafenib Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Terminated
NCT01497808 Phase Ib/II Ipilimumab RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma Active, not recruiting
NCT01512251 Phase Ib/II Buparlisib + Vemurafenib BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Completed
NCT01519323 Phase I Vemurafenib BRIM-P Terminated
NCT01533948 Phase II Axitinib Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery Terminated
NCT01543698 Phase Ib/II Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Active, not recruiting
NCT01565837 Phase II Ipilimumab Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma Unknown status
NCT01585415 Phase I Vandetanib Vemurafenib and White Blood Cell Therapy for Advanced Melanoma Terminated
NCT01586195 Phase II Vemurafenib Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E Terminated
NCT01603212 Phase Ib/II Aldesleukin + Alpha 2 Interferon + Vemurafenib Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor Completed
NCT01619774 Phase II Dabrafenib + Trametinib An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor Completed
NCT01621490 Phase I Ipilimumab Nivolumab PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) Active, not recruiting
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting
NCT01638676 Phase Ib/II Metformin + Vemurafenib A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients Unknown status
NCT01656642 Phase I Atezolizumab + Vemurafenib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma Active, not recruiting
NCT01657591 Phase I Vemurafenib + XL888 Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Active, not recruiting
NCT01659151 Phase II Fludarabine Vemurafenib Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Active, not recruiting
NCT01667419 Phase III Vemurafenib BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma Completed
NCT01682083 Phase III Dabrafenib + Trametinib A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. Active, not recruiting
NCT01682213 Phase II Dabrafenib Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation Completed
NCT01683188 Phase III Aldesleukin + Vemurafenib HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated
NCT01689974 Phase II Ipilimumab Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma Terminated
NCT01696045 Phase II Ipilimumab Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma Terminated
NCT01701037 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery Terminated
NCT01701674 Phase I Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Active, not recruiting
NCT01703507 Phase I Ipilimumab Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases Completed
NCT01708941 Phase II Interferon alpha-2b Ipilimumab Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Active, not recruiting
NCT01721603 Phase II Dabrafenib A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases Terminated
NCT01726738 Phase II Dabrafenib + Trametinib LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations Completed
NCT01738139 Phase I Imatinib + Ipilimumab Ipilimumab and Imatinib Mesylate in Treating Participants With Metastatic or Unresectable Solid Tumors Recruiting
NCT01740297 Phase Ib/II Ipilimumab Talimogene laherparepvec Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting
NCT01754376 Phase II Aldesleukin + Vemurafenib Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma Terminated
NCT01763164 Phase III Dacarbazine Binimetinib Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Active, not recruiting
NCT01765543 Phase I Rifampin + Vemurafenib A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy Completed
NCT01767454 Phase I Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma Completed
NCT01777776 Phase Ib/II Encorafenib Encorafenib + Ribociclib Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Terminated
NCT01781026 Phase II Vemurafenib Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases Completed
NCT01781572 Phase Ib/II Binimetinib + Ribociclib A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma Completed
NCT01810016 Phase I Ipilimumab NY-ESO-1 peptide vaccine NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Terminated
NCT01813214 Phase II Vemurafenib The Effects of Vemurafenib on Immunity in Patients With Melanoma Terminated
NCT01820364 Phase II Binimetinib + Encorafenib Encorafenib + Ribociclib Buparlisib + Encorafenib BGJ398 + Encorafenib Capmatinib + Encorafenib LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Terminated
NCT01826448 Phase I Pexidartinib + Vemurafenib A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma Terminated
NCT01827111 Phase II Ipilimumab + Nab-paclitaxel Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma Active, not recruiting
NCT01835184 Phase I Cabozantinib + Vemurafenib Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery Terminated
NCT01841463 Phase Ib/II Vemurafenib + Voruciclib Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation Suspended
NCT01843738 Phase I Vemurafenib Radiation Use During Vemurafenib Treatment Withdrawn
NCT01844674 Phase I Tizanidine + Vemurafenib A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies Completed
NCT01876212 Phase II Dasatinib Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma Active, not recruiting
NCT01876641 Phase Ib/II Decitabine + Vemurafenib Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Terminated
NCT01894672 Phase II Encorafenib BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation Completed
NCT01897116 Phase I Hydroxychloroquine + Vemurafenib A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Completed
NCT01904123 Phase I WP1066 A Phase I Trial of WP1066 Recruiting
NCT01909453 Phase III Vemurafenib Encorafenib Binimetinib + Encorafenib Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma Active, not recruiting
NCT01940809 Phase II Dabrafenib Trametinib Ipilimumab Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery Active, not recruiting
NCT01941927 Phase II Trametinib + Uprosertib Trametinib With GSK2141795 in BRAF Wild-type Melanoma Unknown status
NCT01942993 Phase II Vemurafenib The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma Terminated
NCT01943422 Phase Ib/II Interferon alpha-2b + Vemurafenib Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma Completed
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed
NCT01950195 Phase I Ipilimumab SRS (Stereotactic Radiosurgery) Plus Ipilimumab Terminated
NCT01950390 Phase II Ipilimumab Bevacizumab + Ipilimumab Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery Active, not recruiting
NCT01961115 Phase II Epacadostat MELITAC 12.1 Peptide Vaccine INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01967823 Phase II Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Recruiting
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01970358 Phase I NeoVax melanoma vaccine A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma Active, not recruiting
NCT01970527 Phase II Ipilimumab Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Completed
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn
NCT01978236 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites Terminated
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01989585 Phase Ib/II Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery Recruiting
NCT01993719 Phase II Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma Recruiting
NCT02009397 Phase Ib/II Sargramostim Ipilimumab A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients Unknown status
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02012231 Phase Ib/II PLX8394 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated
NCT02013804 Phase I MEDI0680 A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Completed
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02020707 Phase I Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery Recruiting
NCT02027935 Phase II Aldesleukin Cyclophosphamide Ipilimumab Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 Active, not recruiting
NCT02027961 Phase Ib/II Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone Completed
NCT02032810 Phase I Panobinostat Ipilimumab Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Active, not recruiting
NCT02036086 Phase II Cobimetinib + Vemurafenib Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases Recruiting
NCT02039947 Phase II Dabrafenib + Trametinib Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain Completed
NCT02043665 Phase I coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Active, not recruiting
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated
NCT02050321 Phase II Acitretin + Vemurafenib A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma Terminated
NCT02054520 Phase II Ipilimumab Immunotherapy Study for Patients With Stage IV Melanoma Active, not recruiting
NCT02065466 Phase Ib/II Bevacizumab + Nab-paclitaxel + Temozolomide Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases Withdrawn
NCT02068079 Phase I Trientine + Vemurafenib A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Withdrawn
NCT02073123 Phase Ib/II Ipilimumab Indoximod Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma Active, not recruiting
NCT02089685 Phase Ib/II Ipilimumab peginterferon alfa-2b Pembrolizumab Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) Active, not recruiting
NCT02094872 Phase II Doxorubicin Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Active, not recruiting
NCT02097225 Phase I Dabrafenib + Onalespib + Trametinib Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery Active, not recruiting
NCT02097732 Phase II Ipilimumab Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery Active, not recruiting
NCT02107755 Phase II Ipilimumab Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Active, not recruiting
NCT02110355 Phase Ib/II AMG 232 + Trametinib AMG 232 + Dabrafenib + Trametinib Dabrafenib + Trametinib A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma Completed
NCT02112032 Phase I peginterferon alfa-2b + Pembrolizumab Treatment of Advanced Melanoma With MK-3475 and Peginterferon Active, not recruiting
NCT02115243 Phase I Ipilimumab Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma Completed
NCT02117362 Phase I Ipilimumab GR-MD-02 Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Completed
NCT02120222 Phase I Selinexor Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery Recruiting
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed
NCT02126579 Phase Ib/II Poly ICLC Long peptide vaccine 7 Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Recruiting
NCT02129075 Phase II NeoVax melanoma vaccine CDX-301 DEC-205-NY-ESO-1 fusion protein vaccine CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma Suspended
NCT02130466 Phase Ib/II Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022) Active, not recruiting
NCT02138292 Phase I Digoxin + Trametinib A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma Completed
NCT02141542 Phase I Tremelimumab MEDI3617 Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma Active, not recruiting
NCT02142218 Phase I Nivolumab Expanded Access Program With Nivolumab to Treat Melanoma No longer available
NCT02143050 Phase Ib/II Dabrafenib + Metformin + Trametinib Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients Recruiting
NCT02145910 Phase I Vemurafenib Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Withdrawn
NCT02156804 Phase II Nivolumab A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) Completed
NCT02158520 Phase II Ipilimumab Bevacizumab + Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Active, not recruiting
NCT02159066 Phase II Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib BGJ398 + Binimetinib + Encorafenib LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Active, not recruiting
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-a ATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Recruiting
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Active, not recruiting
NCT02186249 Phase III Ipilimumab + Nivolumab Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) No longer available
NCT02196181 Phase II Dabrafenib + Trametinib Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Active, not recruiting
NCT02200562 Phase Ib/II Dabrafenib + Ipilimumab Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma Terminated
NCT02210104 Phase I Ipilimumab Cyclophosphamide Adoptive Therapy Using Antigen-Specific CD4 T-Cells Withdrawn
NCT02224781 Phase III Ipilimumab + Nivolumab Dabrafenib + Trametinib Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting
NCT02230306 Phase II Cobimetinib + Vemurafenib Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Terminated
NCT02231775 Phase II Dabrafenib + Trametinib Combi-Neo Study for Stage IV Melanoma Recruiting
NCT02257424 Phase Ib/II Trametinib The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Recruiting
NCT02259231 Phase Ib/II Ipilimumab Nivolumab Omaveloxolone RTA 408 Capsules in Patients With Melanoma - REVEAL Completed
NCT02263508 Phase Ib/II Pembrolizumab Talimogene laherparepvec MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting
NCT02263898 Phase II Binimetinib + Encorafenib Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Withdrawn
NCT02272855 Phase II HF10 + Ipilimumab A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma Completed
NCT02296112 Phase II Trametinib Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Active, not recruiting
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Recruiting
NCT02300935 Phase I Nab-paclitaxel + Trametinib Study of Trametinib and Nab-paclitaxel in Patients With Melanoma Withdrawn
NCT02302339 Phase II Glembatumumab vedotin A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma Terminated
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Active, not recruiting
NCT02306850 Phase II Pembrolizumab Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Completed
NCT02307149 Phase I coxsackievirus A21 Ipilimumab Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma Active, not recruiting
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Active, not recruiting
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Active, not recruiting
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Active, not recruiting
NCT02320058 Phase II Ipilimumab + Nivolumab A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) Active, not recruiting
NCT02320305 Phase I MART-1 antigen GLA-SE + MART-1 antigen MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery Active, not recruiting
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting
NCT02334735 Phase II Poly ICLC Melan-A/MART-1 peptide vaccine NY-ESO-1 peptide vaccine A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence Active, not recruiting
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed
NCT02339324 Phase I Interferon alpha-2b Pembrolizumab Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Active, not recruiting
NCT02339571 Phase II Sargramostim Nivolumab Ipilimumab Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Suspended
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02360579 Phase II LN-144 Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144) Recruiting
NCT02362594 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054) Active, not recruiting
NCT02381314 Phase I Ipilimumab + MGA271 Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer Completed
NCT02382549 Phase Ib/II 6MHP vaccine + Dabrafenib + Trametinib A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61) Recruiting
NCT02385669 Phase Ib/II 6MHP vaccine Ipilimumab A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma Active, not recruiting
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Completed
NCT02388906 Phase III Nivolumab Ipilimumab Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) Active, not recruiting
NCT02400385 Phase II Nivolumab + Sunitinib A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma Withdrawn
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02407171 Phase Ib/II Pembrolizumab Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Recruiting
NCT02413827 Phase Ib/II Nivolumab + Varlilumab DEC-205-NY-ESO-1 fusion protein vaccine Poly ICLC A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma Terminated
NCT02423863 Phase II Poly ICLC In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol Recruiting
NCT02425306 Phase Ib/II Cyclophosphamide 6MHP vaccine Poly ICLC Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma Terminated
NCT02427893 Phase III Cobimetinib Vemurafenib Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma Withdrawn
NCT02428712 Phase Ib/II PLX8394 A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Active, not recruiting
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02434354 Phase I Pembrolizumab A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma Recruiting
NCT02437136 Phase Ib/II Entinostat + Pembrolizumab Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma Active, not recruiting
NCT02452281 Phase Ib/II Vitespen Ipilimumab Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma Withdrawn
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Completed
NCT02460224 Phase Ib/II LAG525 Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02475213 Phase I MGA271 + Pembrolizumab Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer Active, not recruiting
NCT02493361 Phase II Pembrolizumab IL-12 gene Trial of pIL-12/MK-3475 in Metastatic Melanoma Active, not recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Active, not recruiting
NCT02500576 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2) Active, not recruiting
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Recruiting
NCT02506153 Phase III Interferon alpha-2b Pembrolizumab High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Active, not recruiting
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting
NCT02519322 Phase II Ipilimumab Nivolumab Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma Recruiting
NCT02521870 Phase I Pembrolizumab SD-101 A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma Active, not recruiting
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Active, not recruiting
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Active, not recruiting
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02553642 Phase II Nivolumab Ipilimumab Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) Recruiting
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Recruiting
NCT02557321 Phase Ib/II PV-10 Pembrolizumab PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma Recruiting
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02561234 Phase I Pegzilarginase A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Completed
NCT02565992 Phase I coxsackievirus A21 + Pembrolizumab Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma Active, not recruiting
NCT02574533 Phase I Pembrolizumab FANG vaccine Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma Completed
NCT02575404 Phase I GR-MD-02 Pembrolizumab GR-MD-02 Plus Pembrolizumab in Melanoma Patients Recruiting
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Active, not recruiting
NCT02587650 Phase II Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Completed
NCT02591654 Phase I Pembrolizumab MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma Active, not recruiting
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting
NCT02599402 Phase III Ipilimumab + Nivolumab Nivolumab Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Active, not recruiting
NCT02608268 Phase Ib/II Spartalizumab MBG453 Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT02617849 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma Recruiting
NCT02621021 Phase II Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab Recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting
NCT02637531 Phase I Pembrolizumab IPI-549 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Recruiting
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Recruiting
NCT02639546 Phase Ib/II Cobimetinib Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) Recruiting
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting
NCT02644967 Phase Ib/II IMO-2125 + Ipilimumab IMO-2125 + Pembrolizumab A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma Active, not recruiting
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated
NCT02652455 Phase I Nivolumab Aldesleukin + Cyclophosphamide + Fludarabine Urelumab Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma Active, not recruiting
NCT02655822 Phase I Atezolizumab + CPI-444 CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting
NCT02656706 Phase II Ipilimumab + Nivolumab BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial Recruiting
NCT02659540 Phase I Ipilimumab + Nivolumab A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma Active, not recruiting
NCT02681549 Phase II Bevacizumab + Pembrolizumab Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Recruiting
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02706353 Phase Ib/II APX005M + Pembrolizumab APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma Recruiting
NCT02711345 Phase I LTT462 A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers Completed
NCT02714218 Phase III Ipilimumab + Nivolumab A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma Active, not recruiting
NCT02716948 Phase I Nivolumab Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine Recruiting
NCT02718066 Phase Ib/II Chidamide + Nivolumab Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Recruiting
NCT02719015 Phase Ib/II Pembrolizumab + rAd-hCD40L Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma Withdrawn
NCT02721459 Phase I Cobimetinib + Vemurafenib + XL888 XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma Active, not recruiting
NCT02723006 Phase I MLN2480 + Nivolumab MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma Terminated
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT02736123 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone Withdrawn
NCT02740920 Phase II Pembrolizumab Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker Active, not recruiting
NCT02743819 Phase II Ipilimumab + Pembrolizumab Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody Recruiting
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Recruiting
NCT02752074 Phase III Epacadostat + Pembrolizumab Pembrolizumab A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma Active, not recruiting
NCT02760797 Phase I Emactuzumab + RO7009789 A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02796352 Phase II Aldesleukin A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Terminated
NCT02799095 Phase I ALKS 4230 A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors Recruiting
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT02812693 Phase Ib/II Imatinib + Pembrolizumab Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification Withdrawn
NCT02816021 Phase II Azacitidine + Pembrolizumab Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma Recruiting
NCT02818023 Phase I Pembrolizumab + Vemurafenib Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma Active, not recruiting
NCT02819843 Phase II Talimogene laherparepvec A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Recruiting
NCT02823405 Phase I Pembrolizumab + X4P-001 Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA) Completed
NCT02839694 Phase I Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy Withdrawn
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Recruiting
NCT02858869 Phase 0 Pembrolizumab Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Active, not recruiting
NCT02889861 Phase Ib/II IMCgp100 IMCgp100-401 Rollover Study Terminated
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Active, not recruiting
NCT02908672 Phase III Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma Active, not recruiting
NCT02910700 Phase II Nivolumab + Trametinib Dabrafenib + Nivolumab + Trametinib Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma Recruiting
NCT02915666 Phase I Dabrafenib + Digoxin + Trametinib A Clinical Trial of Patients With Melanoma Withdrawn
NCT02922764 Phase I RGX-104 Nivolumab + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT02935790 Phase I Citarinostat + Ipilimumab + Nivolumab Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab Completed
NCT02939300 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma Recruiting
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Recruiting
NCT02961283 Phase I ASN003 Study of ASN003 in Subjects With Advanced Solid Tumors Terminated
NCT02965716 Phase II Pembrolizumab + Talimogene laherparepvec Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Recruiting
NCT02967692 Phase III Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma Recruiting
NCT02970981 Phase II Ipilimumab + Nivolumab Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma Active, not recruiting
NCT02974725 Phase I LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma Recruiting
NCT02974803 Phase II Dabrafenib + Trametinib Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases Active, not recruiting
NCT02981303 Phase II Pembrolizumab + PGG beta-glucan Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Active, not recruiting
NCT02983006 Phase I DS-8273a + Nivolumab Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma Recruiting
NCT02983045 Phase Ib/II Nivolumab + NKTR-214 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) Recruiting
NCT02989064 Phase I MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers Recruiting
NCT02990416 Phase Ib/II A-dmDT390-bisFv(UCHT1) + Pembrolizumab A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma Unknown status
NCT03003676 Phase I Cyclophosphamide + ONCOS-102 + Pembrolizumab A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade Recruiting
NCT03005639 Phase II Cobimetinib + Vemurafenib ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma Withdrawn
NCT03021460 Phase II Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Recruiting
NCT03025256 Phase I Nivolumab Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD) Recruiting
NCT03026517 Phase I Dabrafenib + Phenformin + Trametinib Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma Recruiting
NCT03033576 Phase II Ipilimumab Ipilimumab + Nivolumab Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery Recruiting
NCT03050060 Phase II Nelfinavir + Nivolumab Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Suspended
NCT03068455 Phase III Nivolumab Ipilimumab Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) Active, not recruiting
NCT03088176 Phase I Dabrafenib + Talimogene laherparepvec + Trametinib Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma Recruiting
NCT03089606 Phase II Pembrolizumab Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker Recruiting
NCT03092453 Phase I Cyclophosphamide + Pembrolizumab Dendritic Cell Vaccination in Patients With Advanced Melamona Recruiting
NCT03098160 Phase I Evofosfamide + Ipilimumab Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Recruiting
NCT03101254 Phase Ib/II Cobimetinib + LY3022855 + Vemurafenib LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma Recruiting
NCT03111901 Phase Ib/II Aldesleukin + Pembrolizumab Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer Withdrawn
NCT03126461 Phase II Ipilimumab + Nivolumab SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients Withdrawn
NCT03131908 Phase Ib/II GSK2636771 + Pembrolizumab Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss Recruiting
NCT03132675 Phase II IL-12 gene + Pembrolizumab pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment (PISCES) Recruiting
NCT03132922 Phase I Autologous MAGE-A4 C1032 TCR-modified T cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03149029 Phase II Dabrafenib + Pembrolizumab + Trametinib Pembrolizumab + Trametinib Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma Recruiting
NCT03159117 Phase I PF-06688992 Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma Active, not recruiting
NCT03161431 Phase I SX-682 Pembrolizumab + SX-682 SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab Recruiting
NCT03175432 Phase II Atezolizumab + Bevacizumab Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM) Recruiting
NCT03178851 Phase I Atezolizumab + Cobimetinib A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy Recruiting
NCT03192345 Phase I Cemiplimab + SAR439459 SAR439459 A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors Recruiting
NCT03200847 Phase Ib/II Pembrolizumab + Tretinoin Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Recruiting
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Recruiting
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Recruiting
NCT03241927 Phase II Pembrolizumab Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) Terminated
NCT03259425 Phase II HF10 + Nivolumab Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma Active, not recruiting
NCT03272464 Phase I Dabrafenib + Itacitinib + Trametinib Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Recruiting
NCT03273153 Phase III Pembrolizumab Atezolizumab + Cobimetinib A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma Recruiting
NCT03276832 Phase I Imiquimod + Pembrolizumab Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma Recruiting
NCT03277352 Phase Ib/II Epacadostat + INCAGN01876 + Pembrolizumab INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Active, not recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03301636 Phase II Indoximod + Nivolumab Indoximod + Pembrolizumab A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107) Active, not recruiting
NCT03301896 Phase I LHC165 + Spartalizumab LHC165 Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT03311308 Phase I Metformin + Pembrolizumab Pembrolizumab A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma Recruiting
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Recruiting
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03325101 Phase Ib/II Pembrolizumab Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery Recruiting
NCT03329846 Phase III BMS-986205 + Nivolumab Nivolumab An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma Active, not recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03332589 Phase I E6201 Study of E6201 for the Treatment of Central Nervous System Metastases (CNS) Recruiting
NCT03336606 Phase I MEDI0562 Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma Recruiting
NCT03341143 Phase II Pembrolizumab Fecal Microbiota Transplant (FMT) in Melanoma Patients Recruiting
NCT03347617 Phase II Pembrolizumab Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma Recruiting
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Completed
NCT03384836 Phase Ib/II Pembrolizumab + Propranolol Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery Recruiting
NCT03385486 Phase I TBX-3400 Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors Recruiting
NCT03396211 Phase I Apatinib + Nivolumab Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Recruiting
NCT03396952 Phase II Ipilimumab + Pembrolizumab Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma Recruiting
NCT03407170 Phase II Pembrolizumab Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) Active, not recruiting
NCT03415126 Phase I ASN007 A Study of ASN007 in Patients With Advanced Solid Tumors Recruiting
NCT03420508 Phase II Ensartinib Treating Patients With Melanoma and ALK Alterations With Ensartinib Recruiting
NCT03425461 Phase I Ipilimumab + VX15/2503 Nivolumab + VX15/2503 Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma Recruiting
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting
NCT03445533 Phase III Ipilimumab IMO-2125 + Ipilimumab A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) Recruiting
NCT03455764 Phase Ib/II Dabrafenib + MCS110 + Trametinib A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition Recruiting
NCT03470922 Phase II Nivolumab + Relatlimab Nivolumab A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma Active, not recruiting
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Recruiting
NCT03476174 Phase II Aldesleukin + Pembrolizumab Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma Recruiting
NCT03484923 Phase II LAG525 + Spartalizumab Capmatinib + Spartalizumab Canakinumab + Spartalizumab Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM) Recruiting
NCT03501368 Phase II Ceritinib Study of Ceritinib in Patients With Unresectable Melanoma Recruiting
NCT03502330 Phase I APX005M + Cabiralizumab + Nivolumab APX005M + Cabiralizumab APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Active, not recruiting
NCT03526185 Phase I tumor infiltrating lymphocytes A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03543969 Phase I Cobimetinib + Vemurafenib Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma Recruiting
NCT03554083 Phase I Atezolizumab + Cobimetinib Atezolizumab + Cobimetinib + Vemurafenib Vemurafenib, Cobimetinib, and Atezolizumab in Treating Participants With High-Risk Stage III Melanoma Recruiting
NCT03565406 Phase I Ipilimumab + Mocetinostat + Nivolumab A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Recruiting
NCT03580382 Phase Ib/II CDX-3379 + Trametinib Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma Recruiting
NCT03590054 Phase I Abexinostat + Pembrolizumab A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting
NCT03595683 Phase II EDP1503 + Pembrolizumab Pembrolizumab and EDP1503 in Advanced Melanoma Recruiting
NCT03597282 Phase I Ipilimumab + Nivolumab APX005M + Nivolumab Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC APX005M + NEO-PV-01 + Nivolumab + Poly ICLC Nivolumab + Poly ICLC NEO-PV-01 + Nivolumab + Poly ICLC A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma Recruiting
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Recruiting
NCT03620019 Phase II Denosumab + Pembrolizumab Pembrolizumab Denosumab + Pembrolizumab in Patients With Stage IV Melanoma Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Recruiting
NCT03635983 Phase III Nivolumab Nivolumab + NKTR-214 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Recruiting
NCT03637803 Phase I MRx0518 + Pembrolizumab MRx0518 and Pembrolizumab Combination Study Recruiting
NCT03645928 Phase II LN-144 + Pembrolizumab LN-145 LN-145 + Pembrolizumab Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Recruiting
NCT03646617 Phase II Ipilimumab + Nivolumab Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma Recruiting
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Recruiting
NCT03679767 Phase II INCMGA00012 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Recruiting
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Recruiting
NCT03698019 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery Recruiting
NCT03712358 Phase I PVSRIPO PVSRIPO for Patients With Unresectable Melanoma Recruiting
NCT03719131 Phase II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Rituximab Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Recruiting
NCT03719768 Phase I Avelumab Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Recruiting
NCT03724968 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression Recruiting
NCT03727789 Phase I CBL0137 CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma Recruiting
NCT03743766 Phase II Relatlimab Nivolumab + Relatlimab Nivolumab Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting Recruiting
NCT03757689 Phase II Pembrolizumab Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma Recruiting
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Recruiting
NCT03765229 Phase II Entinostat + Pembrolizumab An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma Recruiting
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Recruiting
NCT03769155 Phase I Nivolumab + VX15/2503 Ipilimumab + VX15/2503 VX15/2503 Ipilimumab + Nivolumab + VX15/2503 VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma Recruiting
NCT03776136 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) Recruiting
NCT03815058 Phase II Pembrolizumab + RO7198457 Pembrolizumab A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma. Recruiting
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Recruiting
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer Recruiting
NCT03820986 Phase III Lenvatinib + Pembrolizumab Pembrolizumab Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03834623 Phase II CC-122 + Nivolumab Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting
NCT03864042 Phase I Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Recruiting
NCT03873818 Phase II Ipilimumab + Pembrolizumab Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain Recruiting
NCT03889782 Phase II Aldesleukin + Nivolumab High Dose IL-2 in Combination With Anti-PD-1 in Metastatic Melanoma and Renal Cell Carcinoma Not yet recruiting
NCT03903640 Phase II Ipilimumab + Nivolumab Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis Recruiting
NCT03911869 Phase II Binimetinib + Encorafenib An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS) Recruiting
NCT03922880 Phase I ADI-PEG 20 + Ipilimumab + Nivolumab Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma Recruiting
NCT03925350 Phase II Niraparib Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation Recruiting
NCT03929029 Phase I Ipilimumab + NeoVax + Nivolumab Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma Not yet recruiting
NCT03957551 Phase Ib/II Cabozantinib + Pembrolizumab Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma Not yet recruiting
NCT03958383 Phase Ib/II hu14.18-IL2 hu14.18-IL2 + Nivolumab hu14.18-IL2 + Ipilimumab + Nivolumab IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma Not yet recruiting
NCT03964233 Phase I BI 754091 + BI 754111 BI 754091 + BI 754111 + BI 907828 BI 754091 + BI 907828 A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111 Recruiting
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Recruiting
NCT03972046 Phase II Dabrafenib + Talimogene laherparepvec + Trametinib Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Recruiting
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Not yet recruiting
NCT03978611 Phase I Ipilimumab + Relatlimab A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment Not yet recruiting
NCT03980314 Phase Ib/II Nivolumab A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection Not yet recruiting
NCT03991130 Phase II Aldesleukin + Nivolumab High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma Recruiting
NCT03999749 Phase II Nivolumab Ipilimumab + Nivolumab + Tocilizumab A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma Recruiting
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Not yet recruiting
NCT04013854 Phase II Ipilimumab + Nivolumab Nivolumab Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab Not yet recruiting